C26-linked rapamycin analogs as mTOR inhibitors
US11685749B2 · kind B2 · utility
3Cited by
76References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2020 |
| Grant date | Jun 27, 2023 |
| Priority date | — |
| Expiry date | Oct 30, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.